Abstract:Malignant gliomas are the most common (60–70%) of all CNS/brain tumors. Annually, thereare approximately five cases of malignant gliomas per 100,000 people, and over 14,000 newcases are diagnosed each year in the United States (1,2). Surgery remains the standard therapyfor primary brain tumors. Although surgery may be combined with radiation therapy and/orfollowed with chemotherapy to destroy remaining cancer cells, patients still have a poorsurvival (3-5). In recent years, Temozolomide (TMZ, Temodar®), a prodrug which undergoesspontaneous conversion to the active alkylating agent (Charts 1 and 2) has emerged as a potentchemotherapeutic agent (6). In combination with radiotherapy, it has been shown tosubstantially increase median survival compared with radiotherapy alone (7). However, TMZhas considerable toxicity, which prevents therapeutic dosage increase. Moreover, anotherlimiting factor of TMZ treatment is tumor resistance to the drug (8-10).Recently, efforts have been made to develop delivery systems for conventionalchemotherapeutic drugs. Polymer-based delivery systems are less immunogenic than proteinbased,e.g. viral vectors, and allow repetitive treatments without acute or chronic host immuneresponse (11-14). Compared with most chemotherapeutic molecules, macromolecules offerseveral advantages, including tumor targeting, increased solubility, enhanced accumulation insolid tumors, decreased general toxicity, increased maximum tolerated doses, circumventionof multidrug resistance and enhanced apoptosis induction (15,16). Nanodrugs can selectivelyaccumulate in tumor through a passive targeting mechanism known as enhanced permeabilityand retention (EPR) effect (17-19). Targeting efficiency is substantially enhanced bycombining nanodrugs with specific antibodies that allow targeting by binding to antigens onthe tumor cell surface (20-22).To avoid systemic side effects by orally administered TMZ, targeting to brain tumor would behighly important. Recently, Brem (23) and Akbar (24) have administered a solid mixture ofbiodegradable polymer and TMZ directly into the brain tumor in animal models. The drug wasprogressively released during degradation of the embedding polymer material and significantlyprolonged the survival time of experimental animals. These methods are invasive, and the drugis applied at the time of surgery. Moreover, gliomas are tumors with the ability to developrecurrences; thus, systemic and targeted delivery of TMZ would be a more beneficial treatmentapproach.Following I.V. administration, we have delivered antisense oligonucleotides specifically tobrain tumor using the targeted nanoconjugate delivery system, Polycefin (21). Thenanoconjugate platform, poly(β-L-malic acid) (PMLA), is biodegradable, non-toxic and nonimmunogenic,containing numerous pendant carboxyl groups suitable for the covalentattachment of prodrugs and other useful molecules. For the delivery into the cytoplasm ofrecipient glioma cells, we conjugated TMZ in its hydrazide form with PMLA along with antitransferrinreceptor (TfR) monoclonal antibody (mAb) for tumor targeting by receptormediatedendocytosis (21) and pH-sensitive trileucine (LLL) for disruption of endosomalmembranes.

Antitumor effect of fibrin glue containing temozolomide against malignant glioma

Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Preparation of transferrin-targeted temozolomide nano-micelles and their anti-glioma effect

Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood–Brain Barrier Opening

Preparation of Temozolomide Nano SustainedRelease Microsphere Material and Its Application in Treatment of Glioma

Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage

Fabrication of pH-responsive temozolomide (TMZ)-clacked tannic acid-altered zeolite imidazole nanoframeworks (ZIF-8) enhance anticancer activity and apoptosis induction in glioma cancer cells

Increased the TMZ concentration in brain by poly(2-ethyl-2-oxazoline) conjugated temozolomide prodrug micelles for glioblastoma treatment

Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation

Use of surface-modified porous silicon nanoparticles to deliver temozolomide with enhanced pharmacokinetic and therapeutic efficacy for intracranial glioblastoma in mice

An injectable in situ hydrogel platform for sustained drug release against glioblastoma

Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid)

Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy

Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation

Evaluation of Temozolomide Treatment for Glioblastoma Using Amide Proton Transfer Imaging and Diffusion MRI

Curcumin combining temozolomide formed localized nanogel for inhibition of postsurgical chemoresistant glioblastoma

Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies

Clinical observation of temozolomide and fotemustine in treating patients with malignant gliomas

A new nano approach to prevent tumor growth in the local treatment of glioblastoma: temozolomide and rutin-loaded hybrid layered composite nanofiber

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy